Skip to content

Prevalence of EILO Among Children With Asthma

The Prevalence of Exercise-Induced Laryngeal Obstruction (EILO) Amongst Children With Asthma' - a Prospective Cross-sectional Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06480084
Enrollment
200
Registered
2024-06-28
Start date
2024-08-01
Completion date
2026-04-30
Last updated
2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in Children, Dyspnea, Exercise-Induced Bronchoconstriction, Exercise-Induced Bronchospasm, Exercise Induced Laryngeal Obstruction, Larynx

Brief summary

The goal of this cross-sectional study is to investigate the prevalence of Exercise Induced Laryngeal Obstruction (EILO) in children with asthma. The hypothesis is that the prevalence will be around 15%, which is higher than the prevalence of 5-8% among the general adolescent population. This is based on the increased prevalence of EILO among adult asthmatics. Participants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire.

Detailed description

Background:Exertional dyspnoea is a common and limiting symptom within the paediatric population. Regular physical activity is paramount for the development of children since it not only promotes cardiorespiratory fitness and muscle strength, but also offers opportunities for self-expression, building confidence and social interaction and integration. It is therefore important to identify the correct cause(s) of exertional dyspnea and reverse them to enable children to be active without symptoms. Exercise induced bronchoconstriction (EIB) is a well-known cause of exertional dyspnoea and is highly specific of childhood asthma. Another less recognized cause of exertional dyspnoea is exercise induced laryngeal obstruction (EILO). EILO is an inappropriate closure of the larynx during strenuous physical activity with no obvious laryngeal pathology at rest, limiting airflow and causing inspiratory stridor. It can co-exist with and mimic symptoms of EIB. Previous studies showed a prevalence of 6% in adolescent populations). However, recent studies revealed a much higher prevalence ofEILO in adults with asthma, up to 25-47%. The prevalence of EILO amongst children with asthma has not yet been investigated. In this study, the aim is to investigate the prevalence of EILO in children with asthma. If EILO is a significant comorbidity of childhood asthma this would implicate that EILO screening should be considered when exercise is a persistent trigger of symptoms in asthmatic children. Correct EILO diagnosis and treatment can lead to adequate treatment of EILO, and to prevention of overtreatment of asthma. Methods: Participants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire. Power analysis: The sample size is calculated based on an estimated prevalence and confidence interval, with a power of 80% and alpha of 0.05. When estimating a prevalence of 15% (CI 10-20%), which is 2 times higher than in the general population (30), this results in a sample size of 196 participants. This was rounded to 200 participants. Dropouts will be replaced until a total number of 200 participants completed both the ECT and CLE test. Statistical analysis for primary outcome: The prevalence of EILO in the study population of adolescents with asthma will be calculated as a percentage with a 95% confidence interval. Baseline characteristics will be compared between participants and non-participants of the CLE test. If there are no significant differences between these groups, it can be assumed that participants represent the studied population. If there are significant differences in baseline characteristics, we will examine the correlation of these characteristics with EILO. An estimated prevalence of EILO will be calculated among the non-participants based on these correlations, and an estimated weighted average will be calculated of the prevalence of EILO among the studied population.

Interventions

DIAGNOSTIC_TESTContinuous Laryngoscopy during Exercise Test (CLE test)

A flexible fiberoptic laryngoscope (Olympus, Tokyo, Japan) is introduced directly through the nose or via a slightly modified Hans Rudolph facemask, and into the pharyngeal space. A modified Bruce protocol with a 60-second incremental intensity step is used (Appendix A) and heart rate is monitored. During the CLE test participants perform incremental exercise on a treadmill until symptom-limiting distress or exhaustion. Forced expiratory flow-volume loops are measured before, during and after the CLE test.

Sponsors

Haukeland University Hospital
CollaboratorOTHER
Medisch Spectrum Twente
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

cross-sectional study

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age 12 to 18 years * Paediatrician diagnosed asthma confirmed with at least one of the following during the last two years: Positive ECT (post-exercise fall in FEV1 \> 10%) / Positive methacholine test (PC20 value of ≤8 mg/mL) / Bronchodilator reversibility (increase in FEV1 ≥12% and/or ≥200 mL following inhalation of 200-400 μg short-acting β2-agonists)

Exclusion criteria

* Other severe cardiopulmonary disease * Inability to perform ECT or CLE test * Inability to perform technically acceptable spirometry * Asthma exacerbation or respiratory tract infection in the last 2 weeks * Short-acting β2-agonists or long-acting β2-agonists use less than respectively 8 and 24 hours before the ECT or CLE test * Oral corticosteroid use in the 4 weeks before the ECT or CLE test

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of EILODuring CLE test. Measured in period until 200 participants are enrolled, expected to be 2 yearsPrevalence of EILO (defined as Maat score grade 2 or higher) in study population, with 95% confidence interval

Secondary

MeasureTime frameDescription
Association of gender with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of gender with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of age with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of age with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test) for continuous variables
Association of length with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of length with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test) for continuous variables
Association of weight with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of weight with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test) for continuous variables
Association of BMI Z score with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of BMI Z score with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test) for continuous variables
Association of hours of moderate-to-vigorous weekly activity with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of hours of moderate-to-vigorous weekly activity with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test) for continuous variables
Association of athletic performance (none/local/regional/national/international) with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of athletic performance (none/local/regional/national/international) with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of type of sports with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of type of sports with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of medication use with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of medication use with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of comorbidities with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsBaseline characteristics of adolescents with and without EILO will be compared. Association of comorbidities with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of recognizable symptoms with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Association of of recognizable symptoms with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of type of reported symptoms with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Association of of type of reported symptoms with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables.
Association of heart rate during exercise with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Association of of heart rate during the exercise test with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test)
Prevalence of EILO with and without current EIBDuring CLE test which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsThe prevalence of EILO among adolescents with and without current EIB will be calculated using a 2x2 table, including 95% confidence intervals. These prevalences will be compared with a Chi-Square test or Fisher's exact test.
Association of maximal % post-exercise fall in FEV1 with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Association of of maximal % post-exercise fall in FEV1 with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test)
Association of maximal exercise intensity (wattage/kg or maximum running pace and slope) with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Exercise intensity will be measured by wattage/kg or maximum running pace and slope and categorized into poor / average / good. Association of of exercise intensity with presence of EILO will be compared using a Chi-square or Fisher's exact test for categorical variables
Association of Asthma Control Test (ACT) with EILODuring CLE test which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsThe ACT score and sub scores will be compared between adolescents with and without EILO using a T-test (or non-parametric Mann-Whitney U test). A receiver operating characteristic curve and 2x2 tables will be used to evaluate the sensitivity and specificity of different cut-off points of these questionnaires.
Association of Exercise-Induced Laryngeal Obstruction Dyspnea Index (EILODI) with EILODuring CLE test which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsEILODI score and sub scores will be compared between adolescents with and without EILO using a T-test (or non-parametric Mann-Whitney U test). A receiver operating characteristic curve and 2x2 tables will be used to evaluate the sensitivity and specificity of different cut-off points of these questionnaires.
Association of Visual Analogue Scale (VAS) with EILODuring CLE test which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsVAS scores will be compared between adolescents with and without EILO using a T-test (or non-parametric Mann-Whitney U test). A receiver operating characteristic curve and 2x2 tables will be used to evaluate the sensitivity and specificity of different cut-off points of these questionnaires.
Association of combination of questionnaire scores (Asthma Control Test (ACT), Exercise-Induced Laryngeal Obstruction Dyspnea Index (EILODI) and/or Visual Analogue Scale (VAS)) with EILODuring CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsQuestionnaire scores (ACT, EILODI, and/or VAS) and sub scores will be compared between adolescents with and without EILO using a T-test (or non-parametric Mann-Whitney U test). A receiver operating characteristic curve and 2x2 tables will be used to evaluate the sensitivity and specificity of different cut-off points of these questionnaires.
Assesment of EIB with CLE compared to ECT testDuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsLung function measurements during the CLE test will be compared to lung function measurements during the ECT using a Bland-Altman plot. A 2x2 table will be made of EIB presence during the ECT and CLE test and outcomes will be compared using a Chi-Square test.
Comparison of age between participants with similar and non-similar EIB results during CLE and ECT testDuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsAge will be compared between participants with similar and non-similar results during the ECT and CLE test using a T-test, or a non-parametric Mann-Whitney U test
Comparison of test duration between participants with similar and non-similar EIB results during CLE and ECT testDuring ECT and CLE test, which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest duration will be compared between participants with similar and non-similar results during the ECT and CLE test using a T-test, or a non-parametric Mann-Whitney U test
Comparison of heart rate between participants with similar and non-similar EIB results during CLE and ECT testDuring ECT and CLE test, which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsHeart rate will be compared between participants with similar and non-similar results during the ECT and CLE test using a T-test, or a non-parametric Mann-Whitney U test
Inter-rater agreement of EILO diagnosis between two participating hospitalsDuring CLE test, which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsInter-rater agreement of the presence of EILO and the Maat score of laryngoscopical images of the larynx, between both hospitals will be described using Cohen's weighted x.
Self-reported discomfort of CLE testAfter the CLE test, which takes approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsThe self-reported discomfort during the CLE test will be calculated based on the DISCO-RC questionnaire scores.
Association of baseline FEV1 (% predicted) with presence of EILODuring ECT and CLE test which each take approximately one hour. Measured in period until 200 participants are enrolled, expected to be 2 yearsTest characteristics of adolescents with and without EILO will be compared. Association of of baseline FEV1 (% predicted) with presence of EILO will be compared using a T-test (or non-parametric Mann Whitney U test)

Countries

Netherlands

Contacts

Primary ContactVera Hengeveld, MD
vera.hengeveld@mst.nl+31 53 487 23 10
Backup ContactMattienne van der Kamp, PhD
m.vanderkamp@mst.nl+31 53 487 23 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026